JW Holdings announced on July 16 that it has won a patent in EU for its source technology for a “multi-biomarker diagnostic kit” that can detect pancreatic cancer during its early stages with a simple blood test.
The company said its technology is an innovative diagnostic platform that helps detect pancreatic cancer at each stage of progression by utilizing the substances expressed in the early and late stages of pancreatic cancer at the same time.
The kit is the first of its kind to test “complement factor b (CFB)” antigens found during the early stage of pancreatic cancer.
Starting with South Korea in 2016, JW Holdings obtained a patent for the technology in Japan last year and China in May this year. It has also applied for a patent in the United States.
An official from JW Holdings said, “With approval from the European Patent Office, the company plans to complete the patent acquisition procedures for major European countries such as Britain, France, and Germany and receive the final approval by the end of this year.”
The global pancreatic cancer diagnosis and treatment market is forecast to post an average annual growth of 13 percent from US$1.73 billion (2 trillion won) in 2015 to US$3.19 billion (3.70 trillion won) in 2020, according to market research firm Mordor Intelligence.